Bell JC - Search Results

1

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH. Heo J, et al. Among authors: bell jc. Mol Ther. 2011 Jun;19(6):1170-9. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22. Mol Ther. 2011. PMID: 21427706 Free PMC article.

2

Recent progress in the battle between oncolytic viruses and tumours.

Parato KA, Senger D, Forsyth PA, Bell JC. Parato KA, et al. Among authors: bell jc. Nat Rev Cancer. 2005 Dec;5(12):965-76. doi: 10.1038/nrc1750. Nat Rev Cancer. 2005. PMID: 16294217 Review.

3

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA. Lun X, et al. Among authors: bell jc. J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57. doi: 10.1093/jnci/djj413. J Natl Cancer Inst. 2006. PMID: 17077357

4

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Power AT, et al. Among authors: bell jc. Mol Ther. 2007 Jan;15(1):123-30. doi: 10.1038/sj.mt.6300039. Mol Ther. 2007. PMID: 17164783 Free article.

5

Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer.

Power AT, Bell JC. Power AT, et al. Among authors: bell jc. Mol Ther. 2007 Apr;15(4):660-5. doi: 10.1038/sj.mt.6300098. Epub 2007 Jan 30. Mol Ther. 2007. PMID: 17264852 Free article. Review.

6

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.

Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, Stojdl DF, Daneshmand M, Speth K, Kirn D, McCart JA, Atkins H, Bell JC. Breitbach CJ, et al. Among authors: bell jc. Mol Ther. 2007 Sep;15(9):1686-93. doi: 10.1038/sj.mt.6300215. Epub 2007 Jun 19. Mol Ther. 2007. PMID: 17579581 Free article.

7

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH. Thorne SH, et al. J Clin Invest. 2007 Nov;117(11):3350-8. doi: 10.1172/JCI32727. J Clin Invest. 2007. PMID: 17965776 Free PMC article.

8

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Kirn DH, et al. PLoS Med. 2007 Dec;4(12):e353. doi: 10.1371/journal.pmed.0040353. PLoS Med. 2007. PMID: 18162040 Free PMC article.

9

Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?

Stanford MM, Breitbach CJ, Bell JC, McFadden G. Stanford MM, et al. Among authors: bell jc. Curr Opin Mol Ther. 2008 Feb;10(1):32-7. Curr Opin Mol Ther. 2008. PMID: 18228179 Review.

10

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH. Park BH, et al. Among authors: bell jc. Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Lancet Oncol. 2008. PMID: 18495536 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

370 results

Search Page